Kei S. Tolliver
Fondateur chez VLP Therapeutics LLC
Profil
Kei S.
Tolliver is the founder of VLP Therapeutics LLC, which was founded in 2012, where she holds the title of General Counsel.
Ms. Tolliver's former jobs include Director-Business Development at S&R Technology Holdings LLC from 2002 to 2013, Director at Sucampo Pharmaceuticals, Inc. in 2013-2014, Director & General Manager at Sucampo Pharma Europe Ltd., Director at Sucampo Pharma LLC, and VP-Operations & Business Development at Sucampo Pharmaceuticals, Inc. from 1998 to 2008.
Ms. Tolliver's education history includes an undergraduate degree from West Virginia University and a graduate degree from Columbus School of Law.
Postes actifs de Kei S. Tolliver
| Sociétés | Poste | Début |
|---|---|---|
VLP Therapeutics LLC
 VLP Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD. | Fondateur | 01/01/2012 |
Anciens postes connus de Kei S. Tolliver
| Sociétés | Poste | Fin |
|---|---|---|
| SUCAMPO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/12/2014 |
| SUCAMPO PHARMACEUTICALS, INC. | Directeur des opérations | 31/05/2008 |
Sucampo Pharma Europe Ltd.
 Sucampo Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mallinckrodt Plc, Sucampo Pharma Europe Ltd. is a British company that develops therapies for gastrointestinal, circulatory, and ophthalmic diseases. The company is based in London, UK. Sucampo Pharma Europe was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on September 28, 2006. | Directeur/Membre du Conseil | - |
Sucampo Pharma LLC
 Sucampo Pharma LLC Miscellaneous Commercial ServicesCommercial Services Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan. | Directeur/Membre du Conseil | - |
S&R Technology Holdings LLC
 S&R Technology Holdings LLC Financial ConglomeratesFinance S&R Technology Holdings LLC provide support to global entrepreneurs and new businesses. It offers managing and growing global ventures. The company was founded by Sachiko Kuno and Ryuji Ueno in 1999 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Formation de Kei S. Tolliver
| West Virginia University | Undergraduate Degree |
| Columbus School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
S&R Technology Holdings LLC
S&R Technology Holdings LLC Financial ConglomeratesFinance S&R Technology Holdings LLC provide support to global entrepreneurs and new businesses. It offers managing and growing global ventures. The company was founded by Sachiko Kuno and Ryuji Ueno in 1999 and is headquartered in Bethesda, MD. | Finance |
Sucampo Pharma LLC
Sucampo Pharma LLC Miscellaneous Commercial ServicesCommercial Services Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan. | Commercial Services |
Sucampo Pharma Europe Ltd.
Sucampo Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mallinckrodt Plc, Sucampo Pharma Europe Ltd. is a British company that develops therapies for gastrointestinal, circulatory, and ophthalmic diseases. The company is based in London, UK. Sucampo Pharma Europe was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on September 28, 2006. | Commercial Services |
VLP Therapeutics LLC
VLP Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD. | Commercial Services |